Adjuvant therapy of cutaneous malignant melanoma: a critical review.
The emergence of revised definitions for the high-risk patient with cutaneous malignant melanoma prompts us to re-examine the current status of adjuvant therapy in this disease. We wish to address the question, "once a cutaneous melanoma is surgically removed and the patient is currently free of disease but at high risk for metastases, what can be done to prevent recurrence"?
D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007978:Levamisole / Q000627:therapeutic use; D008197:Lymph Node Excision; D008545:Melanoma / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011379:Prognosis; D011425:Propionibacterium acnes / Q000276:immunology; D011897:Random Allocation; D012107:Research Design; D012306:Risk; D012878:Skin Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D013997:Time Factors; D014165:Transfer Factor / Q000627:therapeutic use
D001500:BCG Vaccine; D001428:Bacterial Vaccines; D014165:Transfer Factor; D007978:Levamisole